Clareo Health | Phase I/II, Open-label, Multi-center, Two Part Dose-escalation, Safety, Pharmacokinetics (PK) and Efficacy Study of AZD4877 in Patients With Acute Myelogenous Leukemia (AML)
Phase I/II, Open-label, Multi-center, Two Part Dose-escalation, Safety, Pharmacokinetics (PK) and Efficacy Study of AZD4877 in Patients With Acute Myelogenous Leukemia (AML)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Part A: Relapsed or refractory leukemia for which no standard therapies are anticipated to result in a durable remission
Part B: AML who have had no more than two prior relapses or failed to achieve remission after at least one induction treatment.
Patients with prior allogeneic transplants who remain clinically stable for ≥2 weeks or more off immunosuppressive therapy
You may not be if
Promyelocytic acute myelogenous leukemia
Prior allogeneic transplant requiring immunosuppressive therapy or treating physician does not consider patient to be a candidate for allogeneic transplantation.
